Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:CMXI
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for Nuo Therapeutics (OTCMKTS:CMXI)
What is Nuo Therapeutics' stock symbol?
Nuo Therapeutics trades on the OTCMKTS under the ticker symbol "CMXI."
Who are some of Nuo Therapeutics' key competitors?
Some companies that are related to Nuo Therapeutics include Lundin Petroleum A Spon (LNDNY), Banco Popolare (BPSAY), DAILY MAIL&GEN TST SPON (DMTGY), African Barrick Gold Ltd (ABGLY), Solvay S.A. (SVYZY), Tencent Holdings Ltd (TCEHY), Nestle SA (NSRGY), Cable & Wireless Communications Plc (CWIXF), L'Oreal SA (LRLCY), Naspers Limited (NPSNY), Softbank Corp. (Japan) (SFTBY), Allianz SE (AZSEY), Basf Se (BASFY), Volkswagen AG (VLKAY), Reckitt Benckiser Group Plc-ADR (RBGLY), Australia and New Zealand Banking (ANZBY), National Australia Bank (NABZY) and Glencore International PLC, St. Helier (GLCNF).
Who are Nuo Therapeutics' key executives?
Nuo Therapeutics' management team includes the folowing people:
- David Emerson Jorden CPA, Chief Executive Officer, Chief Financial Officer, Director
How do I buy Nuo Therapeutics stock?
Shares of Nuo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuo Therapeutics' stock price today?
MarketBeat Community Rating for Nuo Therapeutics (OTCMKTS CMXI)MarketBeat's community ratings are surveys of what our community members think about Nuo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Nuo Therapeutics stock can currently be purchased for approximately $0.34.
Consensus Ratings for Nuo Therapeutics (OTCMKTS:CMXI) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Nuo Therapeutics (OTCMKTS:CMXI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Nuo Therapeutics (OTCMKTS:CMXI)Earnings History by Quarter for Nuo Therapeutics (OTCMKTS:CMXI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Nuo Therapeutics (OTCMKTS:CMXI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Nuo Therapeutics (OTCMKTS:CMXI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nuo Therapeutics (OTCMKTS:CMXI)Insider Trades by Quarter for Nuo Therapeutics (OTCMKTS:CMXI)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/6/2014||Dean Tozer||Insider||Buy||33,300||$0.36||$11,988.00|| |
|9/12/2014||Dean Tozer||Insider||Buy||40,000||$0.45||$18,000.00|| |
|8/29/2014||Dean Tozer||Insider||Buy||40,000||$0.35||$14,000.00|| |
|8/26/2014||Steven A Shallcross||CFO||Buy||27,500||$0.38||$10,450.00|| |
|8/22/2014||Dean Tozer||Insider||Buy||38,700||$0.38||$14,706.00|| |
|8/20/2014||Dean Tozer||Insider||Buy||48,000||$0.39||$18,720.00|| |
|8/20/2014||Martin P Rosendale||CEO||Buy||25,000||$0.40||$10,000.00|| |
|8/20/2014||Steven A Shallcross||CFO||Buy||52,000||$0.39||$20,280.00|| |
|5/21/2013||David Emerson Jorden||Director||Buy||80,000||$0.50||$40,000.00|| |
|4/19/2013||David Emerson Jorden||Director||Buy||50,000||$0.51||$25,500.00|| |
|4/9/2013||David Emerson Jorden||Director||Buy||75,000||$0.51||$38,250.00|| |
|4/4/2013||Martin P Rosendale||CEO||Buy||17,231||$0.52||$8,960.12|| |
|2/27/2013||David Emerson Jorden||Director||Buy||25,000||$0.52||$13,000.00|| |
|2/22/2013||Aldagen Holdings, Llc||Insider||Buy||281,819||$0.55||$155,000.45|| |
|2/22/2013||David Emerson Jorden||Director||Buy||50,000||$0.53||$26,500.00|| |
|2/22/2013||Martin P Rosendale||CEO||Buy||20,000||$0.53||$10,600.00|| |
|2/19/2013||Guercio Joseph Del||Director||Buy||509,091||$0.55||$280,000.05|| |
|9/14/2012||David Emerson Jorden||Director||Buy||25,000||$0.89||$22,250.00|| |
|9/11/2012||David Emerson Jorden||Director||Buy||8,333||$0.95||$7,916.35|| |
Headline Trends for Nuo Therapeutics (OTCMKTS:CMXI)
Latest Headlines for Nuo Therapeutics (OTCMKTS:CMXI)
No headlines for this company have been tracked by MarketBeat.com
Nuo Therapeutics (CMXI) Chart for Sunday, May, 28, 2017